We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we are going to look at where BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stands against other biotech stocks.
Biotech Sector Set for Growth Amid Innovation and Investor Interest
The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention. The industry has recovered from a challenging 2024 and is poised for significant expansion led by advances in personalized medicine, AI-driven drug discovery, and growing demand for biologics. MarketsandMarkets predicted that the global biotech market would expand by a strong 13%, from $483.0 billion in 2024 to $546.0 billion in 2025. This expansion demonstrates the sector’s tenacity and promise for growth.
The anticipated shift in the Federal Reserve’s interest rate policies is a key driver of this upturn. Biotech is sensitive to changing rate patterns since it requires a large amount of money for costly R&D and clinical testing. Lower rates make more funding available, which helps biotech companies expand, draw in venture capital, and expedite drug development, according to Genetic Engineering and Biotechnology News. A rate drop, according to analysts, may release billions of dollars in investment funds that have been put aside for fledgling biotech firms looking for steady funding.
Investor interest in biotech equities is growing. Biotech is still a high-growth industry with many chances for risk-takers, despite brief ups and downs. The comeback of biotech has been noted by leading investment banks. Citing solid fundamentals, improved clinical outcomes, and a supportive regulatory environment, Goldman Sachs referred to it as an “undervalued opportunity.” According to the firm, biotech equities have tremendous upside potential and an “option-like structure,” particularly when interest rates decline. Analysts at JPMorgan anticipate a recovery in biotech funding at the same time, pointing to indications of stability in manufacturing and research sectors that were negatively impacted by earlier funding shortages. Industry analysts predict that declining interest rates and advantageous investment circumstances may reopen the IPO window for businesses looking for institutional support, even though biotech IPOs have been quiet since 2021.
As gene editing, AI-powered drug discovery, and precision medicine transform how we treat uncommon genetic illnesses, autoimmune diseases, and cancer, scientific advances are also propelling the expansion of biotech. Biotech firms are meeting medical demands in ways that were unthinkable a decade ago because of developments in CRISPR gene editing and cell treatments. Given this, we will take a look at some of the best promising stocks from the biotech sector.
Our Methodology
For this article, we shortlisted stocks that met the following criteria: a market capitalization of over $2 billion, coverage by at least 15 analysts, and a price target upside of more than 20%. We then ranked the selected stocks based on their price target upside, as determined by Wall Street analysts, as of March 21, 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
A pharmaceutical plant manufacturing a proprietary synthetic oral form of a C-type natriuretic peptide.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Analyst Upside: 39.51%
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) develops and markets specialized therapies for rare genetic diseases, focusing on enzyme replacement treatments and other biopharmaceuticals. The business is notable for its commitment to rare diseases; it has successfully introduced eight innovative medications to the market, including therapies for lysosomal storage diseases, severe hemophilia A, and achondroplasia.
The Q4 2024 financial results of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) demonstrated robust development in several important areas. Q4 revenue surged by 16% to $747 million, and its overall revenue grew by 18% to $2.85 billion for the year. Increased acceptance for achondroplasia led to a 56% increase in VOXZOGO sales to $735 million, while enzyme treatments contributed over $1.9 billion, a 12% increase from 2023.
The non-GAAP operating margin increased to 28.6% for the year and 31.1% in Q4, indicating a considerable improvement in the company’s profitability. Revenue growth and operational efficiency were the main drivers of the 69% increase in earnings per share (EPS) to $3.52 and the 88% increase in Q4 EPS to $0.92. Additionally, operating cash flow increased by a staggering 260% to $573 million, giving investors financial flexibility for upcoming projects.
With a 10% growth projection, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) projects revenue in 2025 to reach between $3.1 billion and $3.2 billion. With non-GAAP operating margins between 32% and 33% and EPS between $4.20 and $4.40, margins are expected to continue to expand which suggests sustained profitability and efficiency. Given its strong financial performance and future growth potential, many analysts consider BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) one of the most promising stocks in the biotech sector.
In addition to its financials, the company is developing its therapeutic pipeline; later this year, early clinical data for BMN 333 and BMN 351 (Duchenne Muscular Dystrophy) are anticipated. These changes may spur additional expansion and have a favorable effect on the stock.
Overall, BMRN ranks 10th among the 12 most promising biotech stocks according to wall street analysts. While we acknowledge the potential of biotech companies, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than BMRN but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure. None: This article is originally published on Insider Monkey.